Ozenoxacin Property

Melting point:

>255°C (dec.)

Boiling point:

573.5±50.0 °C(Predicted)

Density 

1.372±0.06 g/cm3(Predicted)

storage temp. 

2-8°C(protect from light)

solubility 

DMSO (Slightly)

pka

6.46±0.50(Predicted)

form 

Solid

color 

Off-White

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H315Causes skin irritation

H319Causes serious eye irritation

H335May cause respiratory irritation

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

Ozenoxacin Chemical Properties,Usage,Production

Description

Ozenoxacin is used to treat impetigo (a skin infection caused by bacteria) in adults and children 2 months of age and older. Ozenoxacin is in a class of medications called antibacterials. It works by killing and stopping the growth of bacteria on the skin. To date, ozenoxacin has been used in trials studying the treatment of impetigo. As of December 11, 2017 the FDA approved Ferrer Internacional S.A.'s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by Staphylococccus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older.

Pharmacokinetics

Although the exposure response relationship for ozenoxacin after it has been applied topically has not yet been studied, a formal relationship is unlikely because systemic exposure of ozenoxacin following its topical application has been measured to be negligible .

Mechanism of action

Ozenoxacin is a quinolone antibiotic drug. And, like most quinolones, ozenoxacin predominately executes its mechanism of action by entering into bacterial cells and acting to inhibit the bacterial DNA replication enzymes DNA gyrase A and topoisomerase IV . As DNA gyrase A and topoisomerase IV are essential to bacterial DNA replication activities including supercoiling, supercoil relaxation, chromosomal condensation, chromosomal decatenation and more, their inhibition is the principal action of ozenoxacin's mechanism and it has been demonstrated to be bactericidal against S. aureus and S. pyogenes organisms.

Description

Ozenoxacin is a novel, nonfluorinated quinolone antibiotic discovered by Toyama Chemical Co. Ltd. and developed by Maruho Co. Ltd. Ozenoxacin was approved by the PMDA of Japan in September 2015 for the treatment of acne and skin infections. Ozenoxacin shows potent antibacterial activity against anaerobic and aerobic, gram-positive and -negative bacteria, especially those implicated in superficial skin infections such as S. aureus, Staphylococcus epidermidis, and Propionibacterium acnes. The mechanism of action of ozenoxacin involves the drug’s affinity for DNA gyrase and DNA topoisomerase IV and upon binding triggers bacterial apoptosis.

Uses

Ozenoxacin is a non-fluorinated topical quinolone. It exhibits antimicrobial activity against?propionibacteria and staphylococci. Ozenoxacin can be used to treat acne and superficial skin infections.

Definition

ChEBI: Ozenoxacin is a member of quinolines.

Synthesis

A U.S. patent filed by co-workers at Toyama describes the only publicly disclosed synthetic approach to this drug.12 The drug?ˉs assembly hinges upon a key Stille coupling between a quinolonyl bromide and a stannylpyridine. Buchwald-Hartwig coupling of commercially available 2,6- dibromotoluene (22) and cyclopropylamine (23) gave Ncyclopropyl- 3-bromo-2-methylaniline 24 in 84% yield , and this step was followed by reaction with diethyl ethoxymethylenemalonate (25) and subsequent cyclization under acidic conditions to secure bromoquinoline 26 in 43% yield over the two-step sequence. Stille coupling of 27 with bromoquinoline 26 resulted in pyridyl quinoline adduct 28 in 80% yield. Saponification of ester 28 followed by acidic removal of the N-acetyl group delivered the active pharmaceutical ingredient ozenoxacin (III) in 75% yield.
The preparation of key stannane 27, which is not commercially available and began with the conversion of commercially available 5-bromo-2- chloro-3-methylpyridine (30) to aminopyridine derivative 31 upon treatment with aqueous methylamine at elevated temperature in a sealed vessel. The resulting aminopyridine was subjected to acetic anhydride in pyridine, resulting in acetamide 32 in good yield, and this coupling was followed by a modest-yielding palladium-catalyzed installation of the stannyl group to deliver subunit 27.